J Korean Med Assoc Search

CLOSE


J Korean Med Assoc > Volume 48(8); 2005 > Article
Park: Management of the Patients with Diabetes Mellitus and Macro- and Microvascular Complications

Abstract

The chronic, mainly vascular complications of diabetes mellitus involve many organs and are responsible for the majority of morbidity and mortality associated with the disease. The vascular complications of diabetes are divided into microvascular and macrovascular complications. Although some macrovascular complications may precede the development of diabetes, they frequently co-associate and present together. The increasing prevalence of diabetes and its association with macrovascular disease have become serious public health concerns. Patients with diabetes who have underlying coronary artery diseases have a different, more complex pathophysiology and a worse prognosis. Optimal management of these patients requires a comprehensive multifactorial approach to prevent microvascular and macrovascular events. In the setting of an acute myocardial infarction (aMI), immediate management should focus on limiting the infarct size using fibrinolytic agents, primary percutaneous intervention, or glycoprotein IIb/IIIa inhibitors. Drug-eluting stents may have an important role in patients with diabetes, who have a higher rate of post-intervention coronary restenosis than in nondiabetic individuals. All patients with aMI should be given aspirin, nitrates, beta-blockers, and angiotensin-converting enzyme inhibitors. Lipid-lowering agents as well as glycemic control have been shown to be effective in decreasing long-term mortality. Despite advances in the management of the vascular complications, the mortality rates of patients with diabetes remain 1.5-to 2-fold greater than those of individuals without diabetes. Maximizing the use of lifesaving therapies proved effective, and a tight metabolic control can further decrease mortality rates. However, many of these lifesaving therapies are underused in patients with diabetes because of the misconception that potential adverse effects may outweigh their benefits. New programs aimed at improving post-infarction quality of care in patients with diabetes, based on guidelines and expert recommendations, have shown promising. However, more efforts should be devoted to the improvement of outcomes related to these public health problems.

References

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

2. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care 2005;28:Suppl 1. 1-79.

3. American Heart Association. Heart Disease and Stroke Statistics 2003;Dallas: TX: 2004 Update.

5. The Writing Team for the Diabetes Control and Complication Trial/Epidemiology of the Diabetes Intervention and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2572.

6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581.

7. Neil HA, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Hunphries SE, et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 2004;90:1431-1437.

9. Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, Braunwald E, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1997;30:141-148.

10. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-1297.

11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.

12. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997;314:1512-1515.

13. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9:259-264.

14. Stone PH, Thompson B, Anderson HV, Kronenberg MW, Gibson RS, Braunwald E, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. JAMA 1996;275:1104-1112.

15. Sprafka JM, Burke GL, Folsom AL, McGoven PG, Hahn LP. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. Diabetes Care 1991;14:537-543.

16. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000;36:355-365.

17. Jokl R, Klein RL, Lopes-Virella MF, Colwell JA. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care 1995;18:1150-1155.

18. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 1996;97:2601-2610.

19. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-537.

20. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fallon JT, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102:2180-2184.

21. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002;40:946-953.

22. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW, Roger VL. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-1825.

23. Weiner DA, Ryan TJ, Parsons L, Fisher LD, Chaitman BR, Tristani FE, et al. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) Registry. Am J Cardiol 1991;68:729-734.

24. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Attali JR, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001;24:339-343.

25. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-1125.

26. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Topol EJ, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997;30:171-179.

27. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Topol EJ, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-2771.

28. Gheorghiade M, Goldstein S. Incomplete versus complete myocardial infarction. Henry Ford Hosp Med J 1991;39:263-264.

29. Fibrinolytic Therapy Trialists(FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-312.

30. Grines C, Patel A, Zijlstra A, Weaver WD, Granger C, Simes RJ. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57.

31. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Lansky AJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.

32. Gaede D, Vedel P, Larsen N, Jensen GVA, Parving HH, Pedersen O. Multifactorial intervention and Cardiovascular dress in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.



ABOUT
ARTICLE CATEGORY

Browse all articles >

ARCHIVES
FOR CONTRIBUTORS
Editorial Office
37 Ichon-ro 46-gil, Yongsan-gu, Seoul
Tel: +82-2-6350-6562    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2024 by Korean Medical Association.

Developed in M2PI

Close layer
prev next